Kyle Munz

Various factors play a role in whether or not a patient is better suited for a chimeric antigen receptor (CAR) T-cell or bispecific monotherapy vs combination therapy, explains Sabarish Ayyappan, MD, City of Hope Cancer Center, Atlanta. As these advancements […]

Community partnerships and inter-organizational collaboration play a critical role when it comes to addressing barriers to cancer care. While treatment access remains a pressing issue, equally important are the challenges that exist beyond treatment, including insurance, transportation, and concerns about

Bispecific and chimeric antigen receptor (CAR) T-cell therapies have emerged as promising therapies for hematologic malignancies and many cancers; however, these advancements have not come without their challenges. Access remains a pertinent barrier to these novel interventions, explained Sabarish Ayyappan,

The advent of immunotherapies, bispecifics, and antibody drug conjugates have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Not only have these advancements helped tailor more targeted interventions, but they have also improved patients’ quality of

Measuring myocardial fibrosis in male and female patients with more severe forms of aortic stenosis (AS) was a useful prognostic tool for each sex, according to new study results. Additionally, male and female patients had comparable extracellular volume fraction (ECV%),

Fibroblast growth factor 21 (FGF21) analogs hold promise as safe and effective therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH); however, these benefits may be exclusive to patients without cirrhotic disease. These findings were published in Annals of Nutrition and

As 2024 came to a close, experts from the realms of oncology, pharmacy, and dermatology gathered to discuss avenues for elevating value in cancer care at The American Journal of Managed Care’s final Institute for Value-Based Medicine event of the

Song Park, MD, on Equitable Access Intertwined With User-Friendly Tech Song Park, MD | Image: University of Washington At a recent Institute for Value-Based Medicine event in Seattle, Washington, Song Park, MD, assistant professor, Department of Dermatology, University of Washington Medicine, offered

Should health care systems shift to more electronic, automated workflows, the industry has an opportunity to save upwards of $20 billion, according to the 2024 CAQH Index. Not only would these initiatives reduce waste and alleviate administrative burdens, but they

A chemotherapy-free combination therapy shows promise for patients with relapsed/refractory (RR) indolent non-Hodgkin lymphoma (iNHL), according to a new real-world study. The analysis, published in Haematologica, highlights the safety and efficacy of a rituximab (Rituxan; Genentech) plus lenalidomide (Revlimid; Bristol